|
Jun 26
|
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
|
|
Jun 26
|
Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst
|
|
Jun 26
|
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
|
|
Jun 26
|
AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
|
|
Jun 25
|
AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio
|
|
Jun 25
|
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
|
|
Jun 25
|
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
|
|
Jun 25
|
AstraZeneca’s trial of Imfinzi for lung cancer failed to meet primary endpoint
|
|
Jun 22
|
3 No-Brainer Stocks to Buy for Under $100 Right Now
|
|
Jun 21
|
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
|
|
Jun 21
|
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
|
|
Jun 20
|
Why Wall Street Is Chasing Ozempic Wannabes
|
|
Jun 11
|
Why AstraZeneca plc (NASDAQ:AZN) is Investors’ One of Favorite International Dividend Stock?
|
|
Jun 10
|
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
|
|
Jun 10
|
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
|
|
Jun 10
|
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
|
|
Jun 10
|
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
|
|
Jun 10
|
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
|
|
Jun 10
|
Most CEOs are defeating attempts to vote down their pay. Can Tesla's Elon Musk do the same?
|
|
Jun 7
|
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
|